Nafamostat API Manufacturer in India

Swapnroop Pharma · WHO-GMP Certified · +91 87670 62101

Nafamostat API

Nafamostat is a synthetic serine protease inhibitor with broad inhibitory activity against enzymes involved in coagulation, fibrinolysis, complement activation and other proteolytic pathways. It inhibits proteases including thrombin, plasmin, kallikrein, trypsin, and coagulation factors such as VIIa, Xa and XIIa.

Nafamostat has a rapid onset and short duration of action and has been used particularly in Asian countries as an anticoagulant during extracorporeal circulation and renal replacement therapies. It has also been used in pharmaceutical applications involving pancreatitis and disseminated intravascular coagulation, depending on the country and approved indication.

The free-base compound is identified by CAS 81525-10-2, molecular formula C₁₉H₁₇N₅O₂, and molecular weight 347.4 g/mol.

About Nafamostat

Nafamostat is also known by the development code FUT-175. Its pharmaceutical activity is primarily associated with rapid inhibition of serine proteases.

For pharmaceutical formulation, Nafamostat is commonly encountered as Nafamostat Mesylate/Mesilate, a salt form containing two methanesulfonic acid components. PubChem lists Nafamostat Mesylate with CAS 82956-11-4 and molecular weight 539.6 g/mol.

Key Features

  • Synthetic serine protease inhibitor
  • Broad-spectrum protease inhibitor
  • Anticoagulant activity
  • Antiproteolytic activity
  • Also known as FUT-175
  • Free-base CAS: 81525-10-2
  • Free-base molecular formula: C₁₉H₁₇N₅O₂
  • Free-base molecular weight: 347.4 g/mol
  • Common pharmaceutical salt: Nafamostat Mesylate
  • Nafamostat Mesylate CAS: 82956-11-4
  • Nafamostat Mesylate molecular weight: 539.6 g/mol
  • Used in pharmaceutical and biomedical applications involving protease inhibition. 

HARMACEUTICAL APPLICATIONS

Nafamostat's most established pharmaceutical applications relate to its anticoagulant and protease-inhibitory properties.

Major Applications

  • Anticoagulation during extracorporeal circulation
  • Continuous renal replacement therapy
  • Hemodialysis-related anticoagulation
  • Management of disseminated intravascular coagulation in certain markets
  • Pancreatitis-related pharmaceutical applications
  • Protease inhibition research
  • Coagulation and fibrinolysis research

Nafamostat is used in Asian countries as an anticoagulant during continuous renal replacement therapy and extracorporeal circulation.

SEO/content recommendation: Do not state that all of these are universally approved indications. Regulatory status and approved uses vary by country.

MECHANISM OF ACTION

Nafamostat works by rapidly inhibiting serine proteases.

It can inhibit several enzymes involved in the coagulation and fibrinolytic systems, including:

  • Thrombin
  • Factor VIIa
  • Factor Xa
  • Factor XIIa
  • Plasmin
  • Kallikrein
  • Trypsin

It also inhibits components of the complement system and pancreatic proteases. This broad protease inhibition contributes to its anticoagulant and antiproteolytic effects.

 

Detailed Specifications

Parameter Specification
Appearance White crystalline powder or crystals
Identification IR & HPLC compliant
Assay (HPLC) 98.0% – 102.0%
Loss on Drying NMT 1.0%
Residue on Ignition NMT 0.5%
Individual Impurity NMT 0.5%
Total Impurities NMT 1.0%
Water Content NMT 1.0%
Get Bulk Quote via WhatsApp